18 kDa translocator protein positron emission tomography facilitates early and robust tumor detection in the immunocompetent SB28 glioblastoma mouse model
Translocator protein
Ex vivo
Fluorodeoxyglucose
Standardized uptake value
DOI:
10.3389/fmed.2022.992993
Publication Date:
2022-10-17T04:35:15Z
AUTHORS (20)
ABSTRACT
Introduction The 18 kDa translocator protein (TSPO) receives growing interest as a biomarker in glioblastoma. Mouse models can serve an important tool for the investigation of biomarkers glioblastoma, but several glioblastoma indicated only low TSPO-PET signals contrast to high human Thus, we aimed investigate imaging syngeneic immunocompetent SB28 mouse model, which is thought closely represent tumor microenvironment (TME) Methods Dynamic TSPO-PET/CT was performed 60 min after injection 13.6 ± 4.2 MBq [ F]GE-180. Contrast enhanced CT (ceCT) acquired prior PET and served assessment volumes attenuation correction. sham mice were imaged at early (week-1; n = 6 SB28, sham) late time-point (week-3; 8 9 inoculation. Standard truth ex vivo obtained time-point. Tracer kinetics analyzed lesion site carotid arteries establish image derived input function (IDIF). ceCT compared with by calculation root-mean-square-errors (RMSE). Volumes distribution (VTmax/mean) calculated using IDIF standardized uptake values (SUVmax/mean) 40–60 time frame. Results Higher rate constants (K1) observed week-1 lesions when week-3 lesions. Highest agreement between achieved 50% maximum threshold (RMSE-VT: 39.7%; RMSE-SUV: 34.4%), similar (RMSE: 30.1%). Lesions had higher signal (VTmax 6.6 2.9 vs. 3.9 0.8, p 0.035; SUVmax 2.3 0.5 1.2 0.1, < 0.001) remained level 5.0 1.6 2.7 0.029; 1.9 0.2, 0.0012). VTmax correlated ( R 2 0.532, 0.001). Conclusion facilitates detection over tumors mirror could valuable translational model study TSPO biomarker.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (38)
CITATIONS (6)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....